Cytek Biosciences Narrows 2025 Revenue Outlook to $196M-$205M Amid Recurring Revenue Growth and New Product Launches

Cytek Biosciences reported Q2 2025 revenue of $45.6 million, a 2.2% decrease compared to Q2 2024. CEO Wenbin Jiang noted lower product revenue in EMEA and APAC, but strong growth in recurring revenue and new product launches. The company narrowed its 2025 revenue outlook to $196-$205 million.

Cytek Biosciences, a leading provider of flow cytometry solutions, released its Q2 2025 earnings report, revealing a mixed performance with earnings per share (EPS) meeting expectations at -$0.04, while revenue fell short at $45.6 million, compared to the forecasted $46.03 million [1]. The stock showed a slight increase of 0.26% in aftermarket trading, reflecting a neutral market reaction to the earnings report.

Key Takeaways:
- EPS: The EPS matched expectations at -$0.04.
- Revenue: Revenue missed forecasts by 0.93%, falling to $45.6 million from the forecasted $46.03 million.
- Service Revenue: Service revenue grew by 18%, while product revenue declined by 9%.
- Net Loss: The company improved its net loss from $10.4 million to $5.6 million year-over-year.
- Cash Position: Cytek maintains a strong cash position with $262 million.
- Market Reaction: The stock price of Cytek Biosciences increased slightly by 0.26% in aftermarket trading.

The company reported a revenue decrease of 2.2% compared to the same quarter last year, despite challenges in the flow cytometry market and reduced capital expenditures. The U.S. market showed positive growth, while other regions faced declines. The company's strong cash position and positive cash flow management were highlighted as key strengths.

Cytek Biosciences narrowed its full-year 2025 revenue outlook to $196-$205 million, expecting a recovery in instrument sales in the second half. The company plans to continue investing in organic growth and remains open to strategic mergers and acquisitions in adjacent markets. The stock's beta of 1.34 indicates higher volatility compared to the market.

During the earnings call, executives noted the company's strengths across pharma customer segments and addressed concerns about market share gains, gross margin expectations, and the potential impact of interest rates and NIH funding on future performance. The company's strong cash position and positive cash flow management were highlighted as key strengths.

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-cytek-biosciences-q2-2025-misses-revenue-forecast-93CH-4175206